Cequent Pharmaceuticals
Cambridge
About Cequent Pharmaceuticals
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases ’ from inflammatory diseases to cancer ’ based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $12.4M
- Funding stage: M&A
- Last round: Series B (Oct 2009)
- Website: cequentpharma.com
- Phone: 617-995-7940
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/cequent-pharmaceuticals-1745736 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.